Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000228838 | SCV000288319 | likely benign | Neuroblastoma, susceptibility to, 3 | 2025-01-30 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV002256159 | SCV002528403 | benign | Hereditary cancer-predisposing syndrome | 2021-03-19 | criteria provided, single submitter | curation | |
Ambry Genetics | RCV002256159 | SCV002714321 | likely benign | Hereditary cancer-predisposing syndrome | 2022-02-13 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV003422146 | SCV004144040 | likely benign | not provided | 2025-02-01 | criteria provided, single submitter | clinical testing | ALK: BP4, BP7 |
Prevention |
RCV003947776 | SCV004766244 | likely benign | ALK-related disorder | 2021-05-11 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |